BNP Paribas Financial Markets Acquires 10,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

BNP Paribas Financial Markets grew its holdings in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 253.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,229 shares of the biotechnology company’s stock after acquiring an additional 10,201 shares during the period. BNP Paribas Financial Markets’ holdings in Aldeyra Therapeutics were worth $77,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. US Bancorp DE purchased a new stake in shares of Aldeyra Therapeutics in the third quarter worth $30,000. SG Americas Securities LLC purchased a new stake in Aldeyra Therapeutics in the 2nd quarter worth $38,000. King Wealth Management Group raised its holdings in Aldeyra Therapeutics by 24.5% during the third quarter. King Wealth Management Group now owns 13,700 shares of the biotechnology company’s stock valued at $74,000 after acquiring an additional 2,700 shares during the period. Intech Investment Management LLC purchased a new position in shares of Aldeyra Therapeutics in the third quarter valued at about $79,000. Finally, Laidlaw Wealth Management LLC boosted its stake in shares of Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 4,150 shares during the period. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Stock Performance

NASDAQ:ALDX opened at $4.86 on Friday. The stock has a 50-day moving average price of $5.13 and a 200 day moving average price of $4.76. Aldeyra Therapeutics, Inc has a 12-month low of $2.71 and a 12-month high of $6.55. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.25). On average, sell-side analysts expect that Aldeyra Therapeutics, Inc will post -0.92 earnings per share for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.